CTOs on the Move

ABS Global

www.absglobal.com

 
Headquartered in DeForest, Wisconsin, ABS Global is the world-leading provider of bovine genetics, reproduction`services, technologies and uddercare products.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Novaseek Research

Novaseek is transforming how biomedical researchers access real-world hospital patient data and human biospecimens. Researchers rely on Novaseek to plan projects, and procure high quality biospecimens and clinical data needed to power discovery. Increasing productivity and de-risking projects across R&D enterprise begins with NovaSeek!

EMD Biosciences

EMD Biosciences, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Canadian Organic Sprout Company

Canadian Organic Sprout Company is a Belleville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ziemer USA INC

Ziemer USA INC is a Wood River, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zymeworks

Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.